1374
Y.-T. XU ET AL.
3
1
13
(
(
d, J ¼ 8.8 Hz, 2H, Ph). P NMR (160 MHz, CDCl ) d (ppm): 6.77. C NMR
3
100 MHz, CDCl ) d (ppm): 110.21, 117.42, 121.43, 134.07.
3
Hexakis-(4-tetrazolylphenyloxy)cyclotriphosphazene (2). IR (KBr):
ꢀ
074.55 cm (C-H), 1612.97, 1496.36, 1441.63 (C H ), 3384 (N-H), 1066.69,
6 4
96.15 (N=N-N), 1274.50, 1208.28, 1189.77 (P=N), 1107.98, 1019.80, 956.11 (P-O-
1
3
9
1
C), 888.26 (P-N). H NMR (400 MHz, DMSO-d ) d (ppm): 7.94 (d, J ¼ 8.8 Hz,
6
3
1
2
8
1
H, Ph), 7.27 (d, J ¼ 8.8 Hz, 2H, Ph). P NMR (160 MHz, DMSO-d ) d (ppm):
6
1
3
.20. C NMR (100 MHz, DMSO-d ) d (ppm): 154.77, 151.37, 128.65, 121.87,
6
þ
þ
21.34. MS: cac. 1101, anl. m=e 1124 (M þNa) , 1140 (M þK) .
Hexakis-(4-cyanoethyltetrazoylphenyloxy)cyclotriphosphazenes (3).
ꢀ
1
Compound 3A: IR (KBr): 3089.84 cm (C-H), 2925.36, 2854.38 (CH CH ),
2
2
1
1
614.26, 1467.09, 1427.28 (C H ), 2256.37 (CN), 1041.51c, 980.22 (N=N-N),
264.57, 1219.95, 1167.70 (P=N), 1101.78, 1018.92, 962.50 (P-O-C), 886.66 (P-N).
6 4
ꢁ
1
Mp: 188–190 C. H NMR (400 MHz, DMSO-d ) d (ppm): 7.90 (d, J ¼ 8.4 Hz,
6
2
H, Ph), 7.19 (d, J ¼ 8.4 Hz, 2H, Ph), 5.05 (t, J ¼ 6.0 Hz, 2H, CH CN), 3.33
2 2 6
2
3
1
(
t, J ¼ 6.4 Hz, 2H, CH CH CN). P NMR (160 MHz, DMSO-d ) d (ppm): 8.62.
1
3
C NMR (100 MHz, DMSO-d ) d (ppm): 163.33, 151.99, 127.95, 123.96, 121.28,
6
þ
1
17.67, 48.29, 17.54., MS: cac. 1420, anl. m=e 1442.9 (M þNa) .
ꢀ
1
Compound 3B: IR (KBr): 3084.97 cm (C-H), 2924.36, 2854.13 (CH CH ),
2
2
1
1
1
7
614.04, 1466.27, 1426.32 (C H ), 2257.29 (CN); 1042.52 (N=N-N), 1268.93,
6 4
216.66, 1179.38 (P=N), 1101.87, 1018.61, 962.60 (P-O-C), 884.92 (P-N). Mp:
ꢁ
1
39–141 C. H NMR (400 MHz, DMSO-d ) d (ppm): 7.89–7.91 (m, 2H, Ph),
6
.18–7.20 (m, 2H, Ph), 5.03–5.06 (m, 2H, CH CH CN), 3.34–3.38 (m, 2H, CH CN).
2
2
2
13
3
1
P NMR (160 MHz, DMSO-d ) d (ppm): 8.61. C NMR (100 MHz, DMSO-d ) d
6
6
(
1
ppm): 163.30–163.34, 151.02, 127.95, 123.92–123.99, 121.00–121.29, 117.68, 48.28,
7.49–17.55.
ACKNOWLEDGMENTS
We thank the National Science Foundation of China (50703013, 20374022)
and Independent Innovative Position of Hubei Province for financial support.
REFERENCES
1
2
. Butler, R. N. Comprehensive Heterocyclic Chemistry; Pergamon: Oxford, UK, 1996; vol. 4.
. Singh, H.; Chala, A. S.; Kapoor, V. K.; Paul, D.; Malhotra, R. K. Medicinal chemistry of
tetrazoles. Prog. Med. Chem. 1980, 17, 83–151.
3
4
5
6
. Herr, R. J. 5-Substituted-1H-tetrazoles as carboxylic acid isosteres: Medicinal chemistry
and synthetic methods. Bioorg. Med. Chem. 2002, 10, 3379–3393.
. Peters, L.; Fr o¨ hlich, R.; Boyd, A. S. F.; Kraft, A. Noncovalent interactions between tetra-
0
zole and an N,N -diethyl-substituted benzamidine. J. Org. Chem. 2001, 66, 3291–3298.
. Gaponik, P. N.; Voitekhovich, S. V.; Ivashkevich, O. A. Metal derivatives of tetrazoles.
Russ. Chem. Rev. 2006, 75, 507–539.
. Xue, H.; Gau, Y.; Twamley, B.; Shreeve, J. M. New energetic salts based on nitrogen-
containing heterocycles. Chem. Mater. 2005, 17, 191–198.